Skip to main content
Terug
Watch Compare

Ovid Therapeutics Inc.

Datakwaliteit: 100%
OVID
NASDAQ Manufacturing Chemicals
€ 2,84
▲ € 0,08 (2,90%)
6 months return
—
Momentum
Neutral
ROE
-34,66%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)1181,27%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-34,66%
Boven sectorgemiddelde (-54,68%)
ROIC-53,41%
Net Margin-240,13%
Op. Margin-585,20%

Veiligheid

Debt / Equity
N/A
Current Ratio4,24
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-24,72 | -5,89
Onder sectorgemiddelde (-1,50)
P/B Ratio9,63
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -38,33 M
Capital efficient — spends only 0,00% of revenue on capex

Price History

Financiële Trends

Koersdoel Analisten

9 analisten
Buy
+76.4%
upside to target
Huidig
€ 2,84
Consensus Target
€ 5,01
€ 3,09
Laag
€ 7,00
Hoog
Vooruitzicht
Forward K/W
-5,89
Forward WPA
-€ 0,47
Omzet Sch.
272.860,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,11 · Rev Est: 48.330,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,14 -€ 0,06 -€ 0,17 € 0,06 — —
Estimate -€ 0,13 -€ 0,15 -€ 0,15 -€ 0,10 -€ 0,11 -€ 0,09
Verrassing -7,69% +59,32% -14,86% +161,22% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 1181,27% Revenue Growth (3Y) -81,96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -34,66% · Net Margin: -240,13%
Revenue (TTM) 7,25 M Net Income (TTM) -17,41 M
ROE -34,66% ROA -24,65%
Gross Margin N/A Operating Margin -585,20%
Net Margin -240,13% Free Cash Flow (TTM) -38,33 M
ROIC -53,41% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 4,24
Debt / Equity N/A Current Ratio 4,24
Interest Coverage N/A Asset Turnover 0,10
Working Capital 22,03 M Tangible Book Value 44,70 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -24,72 · EV/EBITDA: N/A
P/E Ratio -24,72 Forward P/E -5,89
P/B Ratio 9,63 P/S Ratio 59,35
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1577,48 Fwd Earnings Yield N/A
FCF Yield -8,91%
Market Cap 430,43 M Enterprise Value 409,82 M

Per Share

EPS: N/A · FCF/Share: -0,25
EPS (Diluted TTM) N/A Revenue / Share 0,05
FCF / Share -0,25 OCF / Share -0,25
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 220,13% · CapEx/Rev: 0,00%
CapEx / Revenue 0,00% FCF Conversion 220,13%
SBC-Adj. FCF -43,25 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7,25 M 566.000,0 222,80 M 222,50 M —
Net Income -17,41 M -26,43 M -52,34 M -54,17 M 122,83 M
EPS (Diluted) — — -0,74 -0,77 1,76
Gross Profit — — — — —
Operating Income -42,44 M -61,89 M -59,28 M -55,55 M 124,21 M
EBITDA — — — — —
R&D Expenses 25,58 M 36,77 M 28,59 M 24,62 M 46,94 M
SG&A Expenses — — — — —
D&A 273.000,0 613.000,0 568.282,0 512.505,0 237.079,0
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 1,33 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 150,93 M 92,17 M 144,03 M 155,27 M 194,54 M
Total Liabilities 20,27 M 23,94 M 56,23 M 22,99 M 14,80 M
Shareholders' Equity 130,66 M 68,23 M 87,80 M 132,27 M 179,75 M
Total Debt — — — — —
Cash & Equivalents 13,15 M 26,30 M 27,04 M 44,87 M 187,80 M
Current Assets 74,37 M 55,94 M 109,60 M 131,38 M 190,48 M
Current Liabilities 8,29 M 10,52 M 11,47 M 6,99 M 14,80 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -24,7 -1,5
P/B 9,6 1,6
ROE % -34,7 -54,7
Net Margin % -240,1 -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

ETFs Holding This Stock
BSVO logo BSVO EA Bridgeway Omni Small-Cap Value ETF
0,01% weight